{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:11:41Z","timestamp":1778069501993,"version":"3.51.4"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Elevated low-density lipoprotein cholesterol (LDL-C) represents a key causal factor in atherosclerotic cardiovascular disease. Robust evidence demonstrates that early, marked, and sustained reduction of LDL-C is associated with a significant decrease in the risk of major adverse cardiovascular events. However, a substantial proportion of high-risk patients fail to achieve guideline-recommended LDL-C targets with statin therapy alone, thus requiring additional lipid-lowering treatments. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors, particularly the monoclonal antibodies evolocumab and alirocumab, have been shown to reduce LDL-C levels by \u223c60% and to provide clear cardiovascular outcome benefits in secondary prevention. More recently, the VESALIUS-CV trial extended these findings to the setting of primary prevention in high cardiovascular risk patients without prior major cardiovascular events. In this trial, evolocumab achieved a significant and sustained reduction in LDL-C levels and significantly reduced the risk of a first cardiovascular event, including myocardial infarction and ischaemia-driven revascularization, while maintaining a safety profile comparable to placebo. Overall, the available evidence supports the role of evolocumab as an effective and safe strategy for cardiovascular risk reduction across the entire risk continuum, from secondary to primary prevention, underscoring the importance of a personalized therapeutic approach based on the patient's global cardiovascular risk profile.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suag032","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T12:31:10Z","timestamp":1771763470000},"page":"v111-v115","source":"Crossref","is-referenced-by-count":0,"title":["PCSK9 inhibitors conquer primary prevention: the VESALIUS-CV study"],"prefix":"10.1093","volume":"28","author":[{"given":"Laura","family":"Gatto","sequence":"first","affiliation":[{"name":"Cardiovascular Sciences Department, San Giovanni Addolorata Hospital , Rome ,","place":["Italy"]},{"name":"Centro per la Lotta contro l\u2019Infarto, ONLUS Foundation , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Di Bitonto","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Campus Bio-Medico , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Scalia","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ospedale Umberto I , Enna ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7094-6596","authenticated-orcid":false,"given":"Flavio Giuseppe","family":"Biccir\u00e8","sequence":"additional","affiliation":[{"name":"Cardiovascular Sciences Department, San Giovanni Addolorata Hospital , Rome ,","place":["Italy"]},{"name":"Centro per la Lotta contro l\u2019Infarto, ONLUS Foundation , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-2030","authenticated-orcid":false,"given":"Francesco","family":"Prati","sequence":"additional","affiliation":[{"name":"Cardiovascular Sciences Department, San Giovanni Addolorata Hospital , Rome ,","place":["Italy"]},{"name":"Centro per la Lotta contro l\u2019Infarto, ONLUS Foundation , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2026050607120120200_suag032-B1","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026050607120120200_suag032-B2","doi-asserted-by":"crossref","first-page":"e008552","DOI":"10.1161\/CIRCOUTCOMES.121.008552","article-title":"Compounding benefits of cholesterol-lowering therapy for the reduction of Major cardiovascular events: systematic review and meta-analysis","volume":"15","author":"Wang","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026050607120120200_suag032-B3","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/eurjpc\/zwae199","article-title":"Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study","volume":"31","author":"Ray","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026050607120120200_suag032-B4","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: from basic science discoveries to clinical trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ Res"},{"key":"2026050607120120200_suag032-B5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026050607120120200_suag032-B6","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term Evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"key":"2026050607120120200_suag032-B7","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026050607120120200_suag032-B8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40119-022-00300-7","article-title":"Guideline LDL-C threshold achievement in acute myocardial infarction patients: a real-world evidence study demonstrating the impact of treatment intensification with PCSK9i","volume":"12","author":"Mackinnon","year":"2023","journal-title":"Cardiol Ther"},{"key":"2026050607120120200_suag032-B9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026050607120120200_suag032-B10","first-page":"260","article-title":"Effects of lipid lowering therapies on vulnerable plaque features: an updated narrative review of the literature","volume":"10","author":"Biccir\u00e8","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026050607120120200_suag032-B11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ahj.2023.12.004","article-title":"Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial","volume":"269","author":"Bohula","year":"2024","journal-title":"Am Heart J"},{"key":"2026050607120120200_suag032-B12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/advance-article-pdf\/doi\/10.1093\/eurheartjsupp\/suag032\/67295082\/suag032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/28\/Supplement_5\/v111\/67295082\/suag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/28\/Supplement_5\/v111\/67295082\/suag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:12:08Z","timestamp":1778065928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/28\/Supplement_5\/v111\/8513563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":12,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2026,3,11]]},"published-print":{"date-parts":[[2026,5,6]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suag032","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,11]]}}}